<DOC>
	<DOCNO>NCT03059030</DOCNO>
	<brief_summary>Evaluate safety efficacy Yttrium-90 ( 90Y ) radioembolization management thrombocytopenia .</brief_summary>
	<brief_title>Yttrium-90 Radioembolization Cirrhosis-Associated Thrombocytopenia</brief_title>
	<detailed_description>This protocol provide access TheraSphere® treatment patient refractory thrombocytopenia secondary cirrhosis . This protocol utilize splenic artery-directed TheraSphere® treatment .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Male female , 18 year age old , ethnic racial group . Diagnosis cirrhosis portal hypertension serum platelet count less equal 80 × 109/L . [ Rationale : platelet count &lt; 100 × 109/L triple rate liverrelated adverse event ( 3 ) worsens postoperative survival set hepatocellular carcinoma ( HCC ) ( 4 ) . Initial platelet count 80 × 109/L allow majority patient successfully respond 90YRE ( clinical endpoint 50 % platelet count increase ) exceed 100 × 109/L threshold . ] Cirrhosis define one three criterion : Liver Biopsy/histology consistent cirrhotic architectural liver change Portal hypertension ( Hepatic venous pressure gradient ≥10 mm Hg ) Evidence esophageal and/or gastric varix Patients must evidence splenomegaly determine screen crosssectional imaging . No evidence myelosuppression ( e.g . lymphopenia ) evidence normal hematology value Screening Adequate baseline organ function ( exception cirrhosis ) evidence normal BUN/Cr electrolytes screen chemistry . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score 02 Patient life expectancy great 6 month without intervention . Patient willing participate study sign study inform consent . Women childbearing potential must negative serum pregnancy test within 28 day prior screen must breastfeed . Patients serum platelet count le 10 × 109/L . History bleed disorder attribute another cause cirrhosis ( e.g . Von Willebrand disease ) Declines unable provide inform consent History prior partial splenic embolization ( PSE ) splenectomy Use medication know increase platelet count 1 month prior Baseline . History allergy sensitivity TheraSphere® component . History severe peripheral allergy intolerance contrast agent , narcotic , sedative atropine manage medically Contraindications angiography selective visceral catheterization bleeding , diathesis coagulopathy correctable usual therapy hemostatic agent ( e.g . closure device ) Previous randomization trial use 90Y RE Patient must participate enrolled clinical trial investigational device / therapy within 30 day prior randomization Any serious medical condition likely impede successful completion study , certain mental disorder , cardiac arrhythmia , uncontrolled congestive heart failure respiratory disease . Lung dose &gt; 30 Gy determine 99mTcMAA . Patients actively chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>Therasphere®</keyword>
	<keyword>Y90</keyword>
	<keyword>Radioembolization</keyword>
</DOC>